Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Change in Account Payables (2017 - 2025)

Pediatrix Medical (MD) has disclosed Change in Account Payables for 9 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 130.81% to -$1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.7 million, a 150.04% decrease, with the full-year FY2025 number at -$8.7 million, down 150.04% from a year prior.
  • Change in Account Payables was -$1.3 million for Q4 2025 at Pediatrix Medical, down from $760000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $10.1 million in Q3 2022 to a low of -$7.6 million in Q1 2025.
  • A 5-year average of $873947.4 and a median of $760000.0 in 2025 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: plummeted 2812.44% in 2022, then soared 406500.0% in 2024.
  • Pediatrix Medical's Change in Account Payables stood at $966000.0 in 2021, then plummeted by 282.19% to -$1.8 million in 2022, then soared by 99.94% to -$1000.0 in 2023, then skyrocketed by 406500.0% to $4.1 million in 2024, then crashed by 130.81% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Change in Account Payables are -$1.3 million (Q4 2025), $760000.0 (Q3 2025), and -$576000.0 (Q2 2025).